The Technion’s story has been intertwined with Israel’s for more than a century, from laying the foundations for a new nation to shaping its future.
Step inside Israeli innovation at the David and Janet Polak Visitors Center. Experience our 360° immersive movie and tech exhibition. Open to individuals and groups.
Learn MoreAs Seen in Medicalxpress.com
Considered to be one of the greatest revolutions in cancer treatment, immunotherapy enhances the immune system’s ability to target and destroy cancer cells efficiently. One of the key challenges in immunotherapy is the uncertainty regarding patients’ responses—not all patients respond to the treatment, and some may experience side effects without meaningful therapeutic gain. Therefore, there is a need to identify biomarkers that can predict treatment effectiveness based on individual patient data.
New and promising findings on this topic are now presented in a study by Technion researchers published (opens in a new tab) in the journal Cell Genomics. The research was led by Prof. Keren Yizhak and Ph.D. student Ofir Shorer from the Rappaport Faculty of Medicine and the Bruce and Ruth Rappaport Cancer Research Center.
Their study is based on a large-scale meta-analysis of single-cell RNA sequencing and T-cell receptor (TCR) sequencing from cancer patients treated with immunotherapy. This allowed them to examine the genetic characteristics of T-cell clones and their influence on treatment success.